SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
NEW YORK, March 28, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) securities between February 23, 2016 and March 15, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-2. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times.
If you suffered a loss in INSYS you have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-2
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
